Description
Recombinant Human Antibody (MR1) is capable of binding to EGFRvIII dodecapeptide (EEKKGNYVVTDH), expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-EGFRvIII dodecapeptide (EEKKGNYVVTDH) mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-EGFRvIII dodecapeptide (EEKKGNYVVTDH) mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. Necitumumab is a recombinant human IgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. IMC-11F8 is a fully human antibody that has similar antitumor potency as the chimeric cetuximab/Erbitux and might represent a safer therapeutic alternative.
Target
EGFR
Target Alias Names
EGFR, epidermal growth factor receptor, ERBB, HER1, mENA, ERBB1, PIG61, NISBD2, proto-oncogene c-ErbB-1, cell growth inhibiting protein 40, erb-b2 receptor tyrosine kinase 1, cell proliferation-inducing protein 61, receptor tyrosine-protein kinase erbB-1, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Isotype/Mimetic
Human IgG
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression